Matricelf Partners with Sheba Medical Center to Advance Spinal Cord Injury Trial

Event summary

  • Matricelf (TASE: MTLF) has entered a strategic collaboration with Sheba Medical Center to conduct its first-in-human clinical trial for spinal cord injury.
  • The collaboration includes GMP-compliant manufacturing of neural tissue implants at Sheba’s Advanced Biotherapy Center (ABC).
  • The clinical trial will be conducted at Sheba, involving the Spine Surgery Unit (Prof. Ran Harel) and Neurological Rehabilitation Department (Dr. Moshe Bondi).
  • This follows positive preliminary safety data from preclinical studies announced in August 2025.

The big picture

Matricelf’s collaboration with Sheba represents a shift towards integrated clinical development models in regenerative medicine, particularly for complex therapies requiring specialized manufacturing and surgical expertise. This approach, while potentially reducing risk and accelerating timelines, also creates dependency on a single institution. The broader regenerative medicine sector is facing increased regulatory scrutiny and demands for demonstrable clinical outcomes, making this trial a pivotal moment for Matricelf’s long-term viability.

What we're watching

Clinical Efficacy
The success of the first-in-human trial will be critical in validating Matricelf's platform and attracting further investment, and the initial results are expected to be closely scrutinized for signs of meaningful functional improvement in patients.
Manufacturing Scalability
The reliance on Sheba’s ABC for GMP manufacturing creates a potential bottleneck; the ability to scale production to meet future demand will depend on Sheba’s capacity and the efficiency of the collaboration.
Pipeline Expansion
While the initial focus is spinal cord injury, Matricelf’s stated intention to apply the platform to other neurological conditions (traumatic brain injury, Parkinson’s, stroke) means the success of this trial could significantly broaden its therapeutic scope and market opportunity.

Related topics

Biotechnology Clinical Trial Regenerative Medicine